<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0"><channel><title>Yahoo! Finance: GEN.CO News</title><copyright>Copyright (c) 2009 Yahoo! Inc. All rights reserved.</copyright><link>http://finance.yahoo.com/q/h?s=gen.co</link><description>Latest Financial News for GENMAB</description><language>en-us</language><lastBuildDate>Mon, 21 Dec 2009 10:56:37 Etc/GMT</lastBuildDate><image><url>http://us.news2.yimg.com/us.yimg.com/p/fi/pr/40197.gif</url><title>Yahoo! Finance</title><link>http://finance.yahoo.com</link><width>144</width><height>17</height></image><item><title>Genmab&apos;s Financial Calendar for 2010 (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091221/180693.html?.v=1</link><description></description><guid isPermaLink="false">yahoo_finance/776498528</guid><pubDate>Mon, 21 Dec 2009 10:56:37 Etc/GMT</pubDate></item><item><title>UPDATE - Actelion latest casualty as Roche trims portfolio (at Reuters)</title><link>http://us.rd.yahoo.com/finance/external/reuters/rss/SIG=118cks9u6/*http%3A//www.reuters.com/legacyArticle?duid=mtfh94643_2009-12-08_09-46-30_gee5b21b6_newsml&amp;rpc=44&amp;type=marketsNews</link><description></description><guid isPermaLink="false">yahoo_finance/4071421029</guid><pubDate>Tue, 8 Dec 2009 09:46:30 Etc/GMT</pubDate></item><item><title>UPDATE - Genmab says partner Roche to stop antibody development (at Reuters)</title><link>http://us.rd.yahoo.com/finance/external/reuters/rss/SIG=118cks9u6/*http%3A//www.reuters.com/legacyArticle?duid=mtfh60348_2009-12-04_21-10-09_bng417827_newsml&amp;rpc=44&amp;type=marketsNews</link><description></description><guid isPermaLink="false">yahoo_finance/1876984534</guid><pubDate>Fri, 4 Dec 2009 21:10:09 Etc/GMT</pubDate></item><item><title>Genmab Announces RG1507 Update (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091204/179735.html?.v=1</link><description>COPENHAGEN, Denmark -- Summary: Roche to discontinue RG1507 program.</description><guid isPermaLink="false">yahoo_finance/2084403724</guid><pubDate>Fri, 4 Dec 2009 20:09:57 Etc/GMT</pubDate></item><item><title>Genmab Announces Results for the Nine Months Period of 2009 (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091110/178076.html?.v=1</link><description>COPENHAGEN, Denmark -- Summary: Genmab reports results for the nine month period ended September 30, 2009.</description><guid isPermaLink="false">yahoo_finance/1579385703</guid><pubDate>Tue, 10 Nov 2009 17:44:44 Etc/GMT</pubDate></item><item><title>Genmab Announces Start of Ofatumumab Phase III Head to Head Study in DLBCL (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091109/177888.html?.v=1</link><description>COPENHAGEN, Denmark -- Summary: Genmab has initiated a Phase III study of Arzerra ofatumumab in diffuse large B-cell lymphoma.</description><guid isPermaLink="false">yahoo_finance/1195823075</guid><pubDate>Mon, 9 Nov 2009 07:39:42 Etc/GMT</pubDate></item><item><title>Genmab Revises Financial Guidance (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091105/177660.html?.v=1</link><description>COPENHAGEN, Denmark -- Summary: Genmab has revised its 2009 financial guidance and provided information on the financial impact of the reorganization plan announced today.</description><guid isPermaLink="false">yahoo_finance/2041737239</guid><pubDate>Thu, 5 Nov 2009 15:19:00 Etc/GMT</pubDate></item><item><title>Genmab Reorganizes to Build Sustainable Business (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091105/177659.html?.v=1</link><description>COPENHAGEN, Denmark -- Summary: Genmab is planning to reorganize to match resources to ongoing and future needs, sell its U.S. manufacturing facility and reduce headcount by approximately 300 positions.</description><guid isPermaLink="false">yahoo_finance/1596755159</guid><pubDate>Thu, 5 Nov 2009 14:47:05 Etc/GMT</pubDate></item><item><title>Genmab Achieves Milestone in Arzerra Collaboration (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091026/176547.html?.v=1</link><description></description><guid isPermaLink="false">yahoo_finance/410079842</guid><pubDate>Mon, 26 Oct 2009 23:54:57 Etc/GMT</pubDate></item><item><title>GSK and Genmab Receive Accelerated Approval for Arzerra (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091026/176546.html?.v=1</link><description>COPENHAGEN, Denmark and PHILADELPHIA -- Summary: GSK and Genmab have received approval of Arzerra from the FDA for CLL that is refractory to fludarabine and alemtuzumab.</description><guid isPermaLink="false">yahoo_finance/2418797607</guid><pubDate>Mon, 26 Oct 2009 23:50:14 Etc/GMT</pubDate></item><item><title>Declaratory Judgment Action Filed by GSK (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091008/175061.html?.v=1</link><description></description><guid isPermaLink="false">yahoo_finance/2678437522</guid><pubDate>Thu, 8 Oct 2009 15:04:23 Etc/GMT</pubDate></item><item><title>Genmab Announces Positive Top-Line Results for Arzerra(tm) in Front Line NHL (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/090826/172064.html?.v=1</link><description></description><guid isPermaLink="false">yahoo_finance/3237311243</guid><pubDate>Wed, 26 Aug 2009 15:17:16 Etc/GMT</pubDate></item><item><title>Genmab Announces 2009 First Half Year Results (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/090818/171641.html?.v=1</link><description></description><guid isPermaLink="false">yahoo_finance/2266326978</guid><pubDate>Tue, 18 Aug 2009 16:20:43 Etc/GMT</pubDate></item><item><title>Genmab Revises Financial Guidance (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/090817/171591.html?.v=1</link><description></description><guid isPermaLink="false">yahoo_finance/1520804483</guid><pubDate>Mon, 17 Aug 2009 21:03:17 Etc/GMT</pubDate></item><item><title>GlaxoSmithKline and Genmab Announce Results From a Study of Arzerra in Rituximab Refractory Follicular NHL (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/090817/171588.html?.v=3</link><description></description><guid isPermaLink="false">yahoo_finance/1741548551</guid><pubDate>Mon, 17 Aug 2009 20:26:10 Etc/GMT</pubDate></item><item><title>Genmab Announces Preliminary Top-Line Results for Arzerra(TM) in Front Line CLL (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/090811/171240.html?.v=1</link><description></description><guid isPermaLink="false">yahoo_finance/3356623088</guid><pubDate>Tue, 11 Aug 2009 19:57:59 Etc/GMT</pubDate></item><item><title>GlaxoSmithKline and Genmab Announce Top-Line Results for Ofatumumab in Rheumatoid Arthritis (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/090729/170178.html?.v=1</link><description></description><guid isPermaLink="false">yahoo_finance/1941249067</guid><pubDate>Wed, 29 Jul 2009 21:10:52 Etc/GMT</pubDate></item><item><title>Recruitment Completed in Arzerra (Ofatumumab) Phase II Study in Relapsed DLBCL (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/090724/169769.html?.v=2</link><description></description><guid isPermaLink="false">yahoo_finance/1630731113</guid><pubDate>Fri, 24 Jul 2009 14:04:38 Etc/GMT</pubDate></item><item><title>Genmab Announces Lift of Zalutumumab Partial Clinical Hold (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/090716/169130.html?.v=1</link><description></description><guid isPermaLink="false">yahoo_finance/158134715</guid><pubDate>Thu, 16 Jul 2009 15:20:51 Etc/GMT</pubDate></item><item><title>Recruitment Completed in Arzerra(tm) (Ofatumumab) Pivotal CLL Study (GlobeNewswire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/090709/168663.html?.v=1</link><description></description><guid isPermaLink="false">yahoo_finance/3588802683</guid><pubDate>Thu, 9 Jul 2009 12:31:50 Etc/GMT</pubDate></item></channel></rss><!-- c14.finance.sp2.yahoo.com compressed/chunked Tue Dec 22 07:06:29 PST 2009 -->
